A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
2,5-DMA has been encountered as a novel designer drug, with capsules of 200 mg of the hydrobromide salt, equivalent to 170 mg of the hydrochloride salt. It was initially misrepresented as mescaline or MDA before being named DMA. According to Shulgin, this might be an effective dose level that has not been formally clinically explored.
== Commercial performance == Ellipse debuted at number 5 on the Billboard 200 chart and spent a total of 9 weeks on the chart, while also debuting at number 4 on the Billboard Canadian Albums chart and spending a total of 2 weeks on that chart. She also earned three more top 5 entries (including a chart topping entry) in other Billboard charts As of 2011, the album had sold 161,000 copies in the United States. The album sold 48,025 copies worldwide in its first week, which is the most copies Imogen has sold in a singular week.
==== IgE receptor structure ==== FcεR1 is a high affinity IgE-receptor that is expressed on the surface of the mast cell. FcεR1 is a tetramer made of one alpha (α) chain, one beta (β) chain, and two identical, disulfide-linked gamma (γ) chains. The binding site for IgE is formed by the extracellular portion of the α chain that contains two domains that are similar to Ig. One transmembrane domain contains an aspartic acid residue, and one contains a short cytoplasmic tail. The β chain contains, a single immunoreceptor tyrosine-based activation motif ITAM, in the cytoplasmic region. Each γ chain has one ITAM on the cytoplasmic region. The signaling cascade from the receptor is initiated when the ITAMs of the β and γ chains are phosphorylated by a tyrosine kinase. This signal is required for the activation of mast cells. Type 2 helper T cells,(Th2) and many other cell types lack the β chain, so signaling is mediated only by the γ chain. This is due to the α chain containing endoplasmic reticulum retention signals that causes the α-chains to remain degraded in the ER. The assembly of the α chain with the co-transfected β and γ chains mask the ER retention and allows the α β γ complex to be exported to the golgi apparatus to the plasma membrane in rats. In humans, only the γ complex is needed to counterbalance the α chain ER retention.
Sources: en.wikipedia.org
Since the war, the US has had a continued presence of 5,000 troops stationed in Saudi Arabia – a figure that rose to 10,000 during the 2003 conflict in Iraq. Operation Southern Watch enforced the no-fly zones over southern Iraq set up after 1991; oil exports through the Persian Gulf's shipping lanes were protected by the Bahrain-based US Fifth Fleet. Since Saudi Arabia houses Mecca and Medina, Islam's holiest sites, many Muslims were upset at the permanent military presence. The continued presence of U.S. troops in Saudi Arabia after the war was one of the stated motivations behind the 11 September terrorist attacks, the Khobar Towers bombing, and the date chosen for the 1998 US embassy bombings (7 August), which was eight years to the day that US troops were sent to Saudi Arabia. Osama bin Laden interpreted the Islamic prophet Muhammad as banning the "permanent presence of infidels in Arabia". In 1996, bin Laden issued a fatwa, calling for US troops to leave Saudi Arabia. In a December 1999 interview with Rahimullah Yusufzai, bin Laden said he felt that Americans were "too near to Mecca" and considered this a provocation to the entire Islamic world.
== Genome == The cabbage looper genome is 368.2 Mb long (scaffold N50=14.2 Mb; contig N50=621.9 kb; GC content=35.6%) and includes 14,037 protein-coding genes and 270 microRNA (miRNA) genes. The genome and annotation are available at the Cabbage Looper Database. The cabbage looper genome is larger than the Drosophila melanogaster genome (180Mb) but smaller than the Bombyx mori genome (530mb). It encodes at least 108 cytochrome P450 enzymes, 34 glutathione S-transferases, 87 carboxylesterases, and 54 ATP-binding cassette transporters, some of which may be involved in its insecticide resistance. It has the ZW sex-determination system, where females are heterogametic (ZW) and males are homogametic (ZZ). Its telomeres contain (TTAGG)n repeats and transposons belonging to the non-long-terminal-repeat LINE/R1 family, similar to the silkworm. The PiggyBac Transposon, a widely used tool for genetic engineering, was originally discovered in the cabbage looper and subsequently identified in other taxa as well.
== Confession, arrest, and conviction == Wettlaufer entered an inpatient drug rehabilitation program at the Centre for Addiction and Mental Health (CAMH) in Toronto, on September 16, 2016. There, she confessed to CAMH staff about killing or attempting to kill her patients, leading to CAMH notifying the College of Nurses of Ontario (CNO) and the Toronto Police Service. She then emailed CNO to resign as a registered nurse because she had "deliberately harmed patients in [her] care and [was] now being investigated by the police for same", personally called an investigator from CNO, and had CAMH staff fax a four-page handwritten confession. Wettlaufer had confessed to killing patients several times prior to her confession at CAMH, including to a lawyer who advised her to keep it a secret, and was not reported to police. After providing police with a two-hour-long confession, she was formally charged with the eight murders on October 25. After further investigation, she was also charged with four counts of attempted murder and two counts of aggravated assault on January 13, 2017. Wettlaufer waived her right to a preliminary hearing and confessed to all charges in court on June 1. On June 26, she was sentenced to eight concurrent life terms in prison, with no possibility of parole for 25 years. In her confession, Wettlaufer admitted that she "knew the difference between right and wrong" but she was visited by "surges" she could not control. She said, "God or the devil or whatever, wanted me to do it." After one murder, she felt "the surging ...
Factor X, or Stuart-Prower factor, followed, in 1956. This protein was identified in a Ms. Audrey Prower of London, who had a lifelong bleeding tendency. In 1957, an American group identified the same factor in a Mr. Rufus Stuart. Factors XI and XIII were identified in 1953 and 1961, respectively. The view that the coagulation process is a "cascade" or "waterfall" was enunciated almost simultaneously by MacFarlane in the UK and by Davie and Ratnoff in the US, respectively.
Sources: en.wikipedia.org
Bob Stewart, MP for Beckenham, has his conviction for a racially aggravated public order offence quashed following an appeal. 24 February – Lee Anderson is suspended from the Conservative Party after "refusing to apologise" for saying "Islamists" had "got control" of London Mayor Sadiq Khan during an edition of his GB News show the previous day. 25 February – Sunak warns of the dangers of polarisation and hatred in politics following a week of political friction at Westminster. Preet Gill, Labour MP for Birmingham Edgbaston, tells BBC Politics Midlands that receiving death threats appears to have become the "norm" and that her job worries her "in a way I've never been worried before". The SNP announces plans to apply for another parliamentary debate on Gaza in the coming week. The Scottish Government confirms that Economy Secretary Màiri McAllan, who is pregnant, will take maternity leave during the summer, becoming the second Scottish Government minister to do so. 26 February – House of Commons Speaker Sir Lindsay Hoyle rejects the SNP's request for an emergency debate on Gaza. Lee Anderson says that his words were clumsy, but refuses to apologise for his comments about Sadiq Khan. 27 February – A statement from 10 Downing Street says that the prime minister believed Lee Anderson's comments were wrong because they conflated "all Muslims with Islamist extremism". Conservative MP and former minister Paul Scully apologises for suggesting there are "no-go" areas in parts of the London Borough of Tower Hamlets.
According to Kate Brown, the plutonium production plants at Hanford and Mayak in Russia, over a period of four decades, "both released more than 200 million curies of radioactive isotopes into the surrounding environment—twice the amount expelled in the Chernobyl disaster in each instance". Most of this radioactive contamination over the years were part of normal operations, but unforeseen accidents did occur and plant management kept this secret, as the pollution continued unabated. In 2004, a safe was discovered during excavations of a burial trench at the Hanford nuclear site. Inside the safe were various items, including a large glass bottle containing a whitish slurry which was subsequently identified as the oldest sample of weapons-grade plutonium known to exist. Isotope analysis by Pacific Northwest National Laboratory indicated that the plutonium in the bottle was manufactured in the X-10 Graphite Reactor at Oak Ridge during 1944.
Hematologic diseases in which it is positive include ALL, angioimmunoblastic T cell lymphoma, Burkitt lymphoma, chronic myelogenous leukemia in blast crisis (90%), diffuse large B-cell lymphoma (variable), follicular center cells (70%), hairy cell leukemia (10%), and myeloma (some). It tends to be negative in acute myeloid leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and marginal zone lymphoma. CD10 is found on non-T ALL cells, which derive from pre-B lymphocytes, and in germinal center-related non-Hodgkin lymphoma such as Burkitt lymphoma and follicular lymphoma, but not on leukemia cells or lymphomas, which originate in more mature B cells.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.